Drug switching in the Netherlands: a cohort study of 20 active substances.
Pieter J GlerumMarc MaliepaardVincent de ValkDavid M BurgerKees NeefPublished in: BMC health services research (2020)
Drug switching is common in the Netherlands, and most of the drug switches we studied are between generic drugs. The observed annual peak of drug switches is most likely explained by a specific Dutch reimbursement policy. Not only are the data valuable as is, but they also serve as a first step towards elucidating the reasons for the occurrence of these drug switches. In addition, these data can be used to put into perspective the adverse drug reactions associated with drug switching.